查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2128978

PROTAC（標靶蛋白萎縮）市場：依產品類型、給藥途徑、應用、最終用戶、國家及地區分類－產業分析、市場規模、市場佔有率及2026年至2033年預測

PROTAC Targeted Protein Degraders Market, By Product Type, By Route of Administration, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 458 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

PROTAC（標靶蛋白質分解劑）市場預計到 2025 年將達到 5.807 億美元，預計從 2026 年到 2033 年將以 19.6% 的複合年成長率成長。

旨在透過泛素蛋白酵素體系統特異性去除疾病相關蛋白的蛋白嵌合體體（PROTAC）療法的發現、臨床評估、生產和商業化均屬於PROTAC靶向蛋白水解劑的範疇。通常，PROTAC是一種異雙功能分子，由化學連接子、E3泛素連接酶配體和目標蛋白配體組成。 PROTAC透過使目標蛋白更接近E3連接酶來促進其泛素化。這使得蛋白酶體能夠辨識並分解標靶蛋白。

PROTAC（靶向蛋白質分解劑）市場 - 市場動態

對先前被認為難以成藥的標靶的需求不斷成長，以及對標靶蛋白質分解進行臨床檢驗的需求，預計將推動市場需求。

PROTAC 不僅能抑制疾病相關蛋白的活性，還能將其清除，這是推動 PROTAC（標靶蛋白水解劑）市場發展的關鍵因素。傳統的小分子抑制劑通常需要持續與標靶蛋白結合才能維持其治療效果。而 PROTAC 的作用機制則是透過與標靶蛋白和 E3 連接酶形成複合物，可泛素化標靶蛋白，隨後透過蛋白酶體將其分解。這種事件驅動機制提高了針對傳統藥物研發技術難以攻克的標靶的潛力，例如特定的轉錄因子、骨骼蛋白以及突變或異常表達的疾病相關蛋白。隨著針對 KRAS、雄性素受體、BTK、雌激素受體和 BRAF 等蛋白的開發平臺不斷擴展，標靶蛋白水解療法的潛在治療應用也不斷拓展。例如，Astellas正在開發 ASP3082，一種選擇性 KRAS G12D 分解劑，用於治療 KRAS G12D 突變引起的腫瘤。

推動市場擴張的另一個關鍵因素是PROTAC技術從早期實驗室研究階段發展到高階臨床開發階段。越來越多的臨床檢驗推動了基於PROTAC的藥物研發投資，並增強了人們對標靶蛋白分解作為治療策略的信心。 2025年，攜帶ESR1突變、ER陽性/HER2陰性進行性或轉移性乳癌患者對Arvinas和輝瑞的bep-degesterant（ARV-471）均表現出良好的療效。兩家公司都報告了無惡化生存期的顯著延長，為PROTAC療法的未來潛力提供了重要的臨床證據。

PROTAC（標靶蛋白分解劑）市場－市場區隔分析

全球 PROTAC（標靶蛋白水解劑）市場按產品類型、給藥途徑、應用、最終用戶和地區進行細分。

根據產品類型，市場可分為四類：PROTAC、LYTAC、分子黏合劑型分解劑和其他。與分子黏合劑和LYTAC相比，PROTAC經歷了藥物研發流程的演變。製藥和生技公司正透過合作、內部研發和授權合約方式逐步投資PROTAC平台。這些努力推動了PROTAC的臨床發展。例如，C4 Therapeutics的TORPEDO平台正被用於推進多個旨在開發口服分解劑的臨床計畫。

PROTAC（標靶蛋白分解劑）市場－區域分析

北美在靶向蛋白水解劑（PROTAC）市場佔據主導地位。這主要歸功於蛋白水解領域的主要企業，例如Arvinas、Kymera Therapeutics、C4 Therapeutics、Nurix Therapeutics和Monte Rosa Therapeutics，都集中在美國。此外，該地區還受益於雄厚的風險投資和研發資金，以及成熟的製藥和生物技術生態系統。歐洲擁有強大的製藥和研發發展系統，尤其是在英國、瑞士、德國和法國。為了加速療法研發，該地區的企業和學術機構正在開發自己的蛋白質分解技術，並與跨國製藥公司合作。亞太地區也正在蓬勃發展，中國正在擴大其PROTAC研發環境，並開發針對BTK和其他癌症相關蛋白質的蛋白水解劑。

目錄

第1章：標靶蛋白分解劑 (PROTAC) 市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：標靶蛋白分解劑 (PROTAC) 的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：標靶蛋白分解劑（PROTAC）產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：標靶蛋白水解劑（PROTAC）市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：標靶蛋白分解劑（PROTAC）市場概況

  • PROTAC（標靶蛋白分解劑）市場佔有率分析，2025 年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 PROTAC（標靶蛋白分解劑）市場：依產品類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按產品類型
    • PROTAC
    • LYTAC
    • 分子黏合劑型分解劑
    • 其他

第8章 PROTAC（標靶蛋白水解劑）市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 口服
    • 靜脈
    • 皮下
    • 其他

第9章 PROTAC（標靶蛋白質分解劑）市場：按應用領域分類

  • 概述
    • 基於細分市場的市場佔有率分析：按應用領域
    • 腫瘤學
    • 心血管疾病
    • 癌症
    • 神經病學
    • 藥物發現、治療研發
    • 其他

第10章 PROTAC（標靶蛋白分解劑）市場：依最終用戶分類

  • 概述
    • 基於細分市場的市場佔有率分析：按最終用戶分類
    • 醫院和診所
    • 製藥和生物技術公司
    • 研究所
    • 其他

第11章 PROTAC（標靶蛋白分解劑）市場：按地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他中東和非洲國家

第12章：主要供應商分析：PROTAC（標靶蛋白分解劑）產業

  • 競爭對手儀錶板
    • 競爭基準
    • 競爭定位
  • 公司簡介
    • Arvinas, Inc.
    • Pfizer Inc.
    • Kymera Therapeutics, Inc.
    • C4 Therapeutics, Inc.
    • Nurix Therapeutics, Inc.
    • Bristol Myers Squibb
    • BeiGene/BeOne Medicines
    • Astellas Pharma Inc.
    • Novartis AG
    • Genentech
    • AstraZeneca PLC
    • Monte Rosa Therapeutics
    • Captor Therapeutics
    • Gyre Therapeutics
    • Foghorn Therapeutics
    • Ranok Therapeutics
    • 其他

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7420

PROTAC Targeted Protein Degraders Market size was valued at USD 580.7 Million in 2025, expanding to a CAGR of 19.6% from 2026 to 2033.

The discovery, clinical assessment, production, and marketing of proteolysis-targeting chimera (PROTAC) treatments intended to specifically remove disease-associated proteins via the ubiquitin-proteasome system is all included in the PROTAC targeted protein degraders. Typically, PROTACs are heterobifunctional molecules made up of a chemical linker, an E3 ubiquitin ligase ligand, and a target-protein ligand. PROTACs facilitate the ubiquitination of the target protein by bringing it in close proximity to E3 ligase. This causes the proteasome to recognize and degrade the target protein.

PROTAC Targeted Protein Degraders Market- Market Dynamics

Growing demand for previously difficult-to-drugs targets and need for clinical validation for targeted protein degradation are expected to propel market demand

The ability of PROTACs to eliminate disease-associated proteins rather than merely inhibit their activity is a key factor driving the development of the targeted protein degraders market. In order to continue their therapeutic effects, conventional small-molecule inhibitors usually need to bind to their target proteins continuously. On the other hand, PROTACs work by creating a target-PROTAC-E3 ligase complex, which causes the target protein to be ubiquitinated and subsequently broken down by the proteasome. This event-driven mechanism increases the possibility of addressing proteins, such as certain transcription factors, scaffolding proteins, and mutant or aberrantly expressed disease-driving proteins, that have proven challenging to modify using traditional drug-discovery techniques. The potential therapeutic uses of targeted protein degradation are being expanded by the expanding development pipeline that targets proteins including KRAS, androgen receptor, BTK, estrogen receptor, and BRAF. For example, Astellas is developing ASP3082, a selective KRAS G12D degrader, to treat tumors caused by the KRAS G12D mutation.

Another significant factor propelling market expansion is the advancement of PROTAC technology from early-stage laboratory research to sophisticated clinical development. Growing clinical validation is boosting investment in PROTAC-based medication research and bolstering trust in targeted protein degradation as a therapeutic strategy. In 2025, patients with ESR1-mutant, ER-positive/HER2-negative advanced or metastatic breast cancer responded favourably to Arvinas and Pfizer's vepdegestrant (ARV-471). A statistically significant increase in progression-free survival was reported by the firms, offering crucial clinical proof of the promise of PROTAC treatments.

PROTAC Targeted Protein Degraders Market- Segmentation Analysis:

The Global PROTAC Targeted Protein Degraders Market is segmented on the basis of Product Type, Route of Administration, Application, End User, and Region.

The market is divided into four categories based on Product Type: PROTAC, LYTAC, molecular glue degraders, and others. Compared to molecular glues and LYTACs, PROTACs have evolved via the drug-development pipeline. Through partnerships, internal research, license agreements, and other means, pharmaceutical and biotechnology businesses are gradually investing in PROTAC platforms. PROTAC's advanced clinical development activities are made possible by these initiatives. For instance, the TORPEDO platform from C4 Therapeutics has been used to progress several clinical programs and is intended to produce orally accessible degraders.

PROTAC Targeted Protein Degraders Market- Geographical Insights

North America holds a strong position in the targeted protein degraders market, primarily due to the concentration of leading protein degradation companies in the United States, including Arvinas, Kymera Therapeutics, C4 Therapeutics, Nurix Therapeutics, and Monte Rosa Therapeutics. Additionally, the region benefits from robust venture and research financing, a well-established pharmaceutical and biotechnology ecosystem, etc. Particularly in the UK, Switzerland, Germany, and France, Europe boasts a robust pharmaceutical and research ecosystem. To speed up therapeutic research, businesses and academic institutions in the region are creating exclusive protein degradation technologies and collaborating with multinational pharmaceutical firms. With China creating an expanding PROTAC research and development environment and producing degraders against targets including BTK and other cancer-related proteins, Asia-Pacific is also gaining momentum.

China PROTAC Targeted Protein Degraders Market- Key Insights

With rising investment in cutting-edge drug development and a developing biotechnology sector, China has become a significant growth contributor to the Asian market for targeted protein degraders. The increasing number of domestic businesses developing unique protein-degradation platforms is a major factor in the growth of the Chinese market. Programs based on targeted protein breakdown have been created or advanced by companies including BeOne Medicines (BeiGene), Cullgen, Haisco Pharmaceutical, Kintor Pharmaceutical, Hinova Pharmaceuticals, and Lynk Pharmaceuticals. However, due to issues with molecular characteristics, oral bioavailability, etc., China's PROTAC market is still in a comparatively early stage of commercialization. Therefore, it is anticipated that successful regulatory approvals and ongoing development of clinical-stage candidates will be crucial for converting China's growing market.

PROTAC Targeted Protein Degraders Market- Competitive Landscape:

The market for PROTAC-targeted protein degraders is fiercely competitive. Degradation potency, target selectivity, E3 ligase recruitment, oral bioavailability, pharmacokinetic performance, tissue penetration, degradation efficiency, clinical efficacy, safety, intellectual property protection, and development schedules are among the key competitors. Additionally, businesses are funding the development of the E3 ligase toolset and next-generation degrader platforms. Collaborations, licensing contracts, and strategic alliances with pharmaceutical companies are crucial competitive strategies that businesses use. For instance, Kymera Therapeutics and Gilead Sciences strategically partnered in August 2025 to develop oral molecular-glue degraders that target CDK2.

Recent Developments:

In September 2025, Arvinas and Pfizer declared their plans to jointly identify a third-party partner to out-license and commercialize vepdegestrant, their oral estrogen receptor PROTAC degrader.

In May 2025, C4 Therapeutics reported continued progress across its targeted protein degradation pipeline and advanced its TORPEDO platform, which is designed to develop highly catalytic and orally bioavailable protein degraders.

In 2026, Gyre Therapeutics acquired Cullgen, strengthening the combined company's presence across the U.S. and China and highlighting the increasing strategic importance of China's capabilities in targeted protein degradation and innovative drug discovery.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PROTAC TARGETED PROTEIN DEGRADERS MARKET KEY PLAYERS

  • Arvinas, Inc.
  • Pfizer Inc.
  • Kymera Therapeutics, Inc.
  • C4 Therapeutics, Inc.
  • Nurix Therapeutics, Inc.
  • Bristol Myers Squibb
  • BeiGene / BeOne Medicines
  • Astellas Pharma Inc.
  • Novartis AG
  • Genentech
  • AstraZeneca PLC
  • Monte Rosa Therapeutics
  • Captor Therapeutics
  • Gyre Therapeutics
  • Foghorn Therapeutics
  • Ranok Therapeutics
  • Others

GLOBAL PROTAC TARGETED PROTEIN DEGRADERS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2020-2033

  • PROTAC
  • LYTAC
  • Molecular glue degraders
  • Others

GLOBAL PROTAC TARGETED PROTEIN DEGRADERS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020-2033

  • Oral
  • Intravenous
  • Subcutaneous
  • Others

GLOBAL PROTAC TARGETED PROTEIN DEGRADERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020-2033

  • Oncology
  • Cardiovascular Disorders
  • Cancer
  • Neurology
  • Drug Discovery, Therapy Development
  • Others

GLOBAL PROTAC TARGETED PROTEIN DEGRADERS MARKET, BY END USER- MARKET ANALYSIS, 2020-2033

  • Hospitals & Clinics
  • Pharmaceutical & Biotech Companies
  • Research Laboratories
  • Others

GLOBAL PROTAC TARGETED PROTEIN DEGRADERS MARKET, BY REGION- MARKET ANALYSIS, 2020-2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. PROTAC Targeted Protein Degraders Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. PROTAC Targeted Protein Degraders Market Snippet by Product Type
    • 2.1.2. PROTAC Targeted Protein Degraders Market Snippet by Route of Administration
    • 2.1.3. PROTAC Targeted Protein Degraders Market Snippet by Application
    • 2.1.4. PROTAC Targeted Protein Degraders Market Snippet by End User
    • 2.1.5. PROTAC Targeted Protein Degraders Market Snippet by Country
    • 2.1.6. PROTAC Targeted Protein Degraders Market Snippet by Region
  • 2.2. Competitive Insights

3. PROTAC Targeted Protein Degraders Key Market Trends

  • 3.1. PROTAC Targeted Protein Degraders Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. PROTAC Targeted Protein Degraders Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. PROTAC Targeted Protein Degraders Market Opportunities
  • 3.4. PROTAC Targeted Protein Degraders Market Future Trends

4. PROTAC Targeted Protein Degraders Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. PROTAC Targeted Protein Degraders Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. PROTAC Targeted Protein Degraders Market Landscape

  • 6.1. PROTAC Targeted Protein Degraders Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. PROTAC Targeted Protein Degraders Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2025 & 2033 (%)
    • 7.1.2. PROTAC
    • 7.1.3. LYTAC
    • 7.1.4. Molecular glue degraders
    • 7.1.5. Others

8. PROTAC Targeted Protein Degraders Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 8.1.2. Oral
    • 8.1.3. Intravenous
    • 8.1.4. Subcutaneous
    • 8.1.5. Others

9. PROTAC Targeted Protein Degraders Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 9.1.2. Oncology
    • 9.1.3. Cardiovascular Disorders
    • 9.1.4. Cancer
    • 9.1.5. Neurology
    • 9.1.6. Drug Discovery, Therapy Development
    • 9.1.7. Others

10. PROTAC Targeted Protein Degraders Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 10.1.2. Hospitals & Clinics
    • 10.1.3. Pharmaceutical & Biotech Companies
    • 10.1.4. Research Laboratories
    • 10.1.5. Others

11. PROTAC Targeted Protein Degraders Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. PROTAC Targeted Protein Degraders Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. PROTAC Targeted Protein Degraders Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. PROTAC Targeted Protein Degraders Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. PROTAC Targeted Protein Degraders Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. PROTAC Targeted Protein Degraders Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- PROTAC Targeted Protein Degraders Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Arvinas, Inc.
    • 12.2.2. Pfizer Inc.
    • 12.2.3. Kymera Therapeutics, Inc.
    • 12.2.4. C4 Therapeutics, Inc.
    • 12.2.5. Nurix Therapeutics, Inc.
    • 12.2.6. Bristol Myers Squibb
    • 12.2.7. BeiGene / BeOne Medicines
    • 12.2.8. Astellas Pharma Inc.
    • 12.2.9. Novartis AG
    • 12.2.10. Genentech
    • 12.2.11. AstraZeneca PLC
    • 12.2.12. Monte Rosa Therapeutics
    • 12.2.13. Captor Therapeutics
    • 12.2.14. Gyre Therapeutics
    • 12.2.15. Foghorn Therapeutics
    • 12.2.16. Ranok Therapeutics
    • 12.2.17. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us